Advertisement · 728 × 90
#
Hashtag
#Givinostat
Advertisement · 728 × 90
Preview
New Insights on Givinostat for Duchenne Muscular Dystrophy Highlighted at 2026 MDA Conference ITF Therapeutics has unveiled significant findings regarding Givinostat for Duchenne Muscular Dystrophy at the 2026 MDA Conference, focusing on safety and efficacy.

New Insights on Givinostat for Duchenne Muscular Dystrophy Highlighted at 2026 MDA Conference #United_States #ITF_Therapeutics #Concord #Duchenne_Muscular_Dystrophy #givinostat

0 0 0 0
Preview
ITF Therapeutics Unveils Promising Findings at 2026 MDA Clinic Conference ITF Therapeutics LLC shares significant data on givinostat for Duchenne muscular dystrophy at the 2026 MDA Clinical Conference. Learn about their presentations.

ITF Therapeutics Unveils Promising Findings at 2026 MDA Clinic Conference #USA #Orlando #ITF_Therapeutics #DUVYZAT #givinostat

0 0 0 0
Preview
New Insights on Givinostat's Efficacy for Duchenne Muscular Dystrophy Unveiled at NMSG Meeting 2025 Recent findings on givinostat's use for treating Duchenne muscular dystrophy were presented at the 2025 NMSG Annual Scientific Meeting in Italy, focusing on flexible dosing and outcomes.

New Insights on Givinostat's Efficacy for Duchenne Muscular Dystrophy Unveiled at NMSG Meeting 2025 #United_States #Massachusetts #ITF_Therapeutics #DMD #givinostat

0 0 0 0
Post image

🔗Lee el artículo completo en el siguiente link: theakarifoundation-pr.org/blog

#TheAkariFoundation #sanantoniotexas #enfermedadesraras #DistrofiaMuscularDeDuchenne #duchenneenespañol #ITFTherapeutics #Givinostat #DUVYZAT #somoselcorazóndeladistrofia #AkariAgosto

1 0 0 0
ITF Therapeutics Announces Publication of Positive Long-Term Data Reinforcing Duvyzat (Givinostat) Efficacy and Safety as a Treatment for Duchenne Muscular Dystrophy

Positive long-term safety and efficacy data for Duvyzat (Givinostat) as a treatment for Duchenne muscular dystrophy (DMD) were published today by ITF Therapeutics, an Italfarmaco affiliate. The data came from the company's open-label extensions of its Phase 2 and Phase 3 (EPIDYS) trials.

🎈 New data published in Annals of Clinical and Translational Neurology show that long-term treatment with givinostat can significantly delay loss of key mobility functions in patients with Duchenne muscular dystrophy.

🎈 Meaningful clinical benefit was observed across treatment groups, regardless of disease stage at initiation.

🎈 Givinostat remained well-tolerated during extended use, consistent with previous clinical trials.

🎈 Average follow-up in the extension study exceeded 36 treatment months, with some patients receiving treatment for over eight years since initiating givinostat treatment.

#givinostat #duvyzat

👉 Read More: DMDWarrioR.com

ITF Therapeutics Announces Publication of Positive Long-Term Data Reinforcing Duvyzat (Givinostat) Efficacy and Safety as a Treatment for Duchenne Muscular Dystrophy Positive long-term safety and efficacy data for Duvyzat (Givinostat) as a treatment for Duchenne muscular dystrophy (DMD) were published today by ITF Therapeutics, an Italfarmaco affiliate. The data came from the company's open-label extensions of its Phase 2 and Phase 3 (EPIDYS) trials. 🎈 New data published in Annals of Clinical and Translational Neurology show that long-term treatment with givinostat can significantly delay loss of key mobility functions in patients with Duchenne muscular dystrophy. 🎈 Meaningful clinical benefit was observed across treatment groups, regardless of disease stage at initiation. 🎈 Givinostat remained well-tolerated during extended use, consistent with previous clinical trials. 🎈 Average follow-up in the extension study exceeded 36 treatment months, with some patients receiving treatment for over eight years since initiating givinostat treatment. #givinostat #duvyzat 👉 Read More: DMDWarrioR.com

ITF Therapeutics Announces Publication of Positive Long-Term Data Reinforcing Duvyzat (Givinostat) Efficacy and Safety as a Treatment for Duchenne Muscular Dystrophy

#givinostat #duvyzat

👉 Read More: DMDWarrioR.com

0 0 0 0
Preview
Duchenne-Muskeldystrophie: Givinostat im Handel Im Juli wurde mit Givinostat (Duvyzat® 8,86 mg/ml Suspension zum Einnehmen, Italfarmaco) ein neuer Wirkstoff und eine neue Therapieoption bei Duchenne-...

Im Juli wurde mit #Givinostat (Duvyzat® 8,86 mg/ml Suspension zum Einnehmen, Italfarmaco) ein neuer Wirkstoff und eine neue Therapieoption bei Duchenne-Muskeldystrophie auf dem deutschen Markt eingeführt.

0 0 0 0
EMA Recommends EU Approval for Duvyzat (givinostat) to Treat Duchenne Muscular Dystrophy
EMA has recommended granting a conditional marketing authorisation in the European Union (EU) for Duvyzat (givinostat) as a treatment for Duchenne muscular dystrophy (DMD) in patients from the age of six who are able to walk.
The European Medicines Agency (EMA) has suggested that Duvyzat (givinostat) be given a conditional marketing authorization in the EU to treat Duchenne muscular dystrophy (DMD) in individuals who can walk starting at age six. Duvyzat is a suspension that is given orally in conjunction with corticosteroid therapy.

EMA Recommends EU Approval for Duvyzat (givinostat) to Treat Duchenne Muscular Dystrophy EMA has recommended granting a conditional marketing authorisation in the European Union (EU) for Duvyzat (givinostat) as a treatment for Duchenne muscular dystrophy (DMD) in patients from the age of six who are able to walk. The European Medicines Agency (EMA) has suggested that Duvyzat (givinostat) be given a conditional marketing authorization in the EU to treat Duchenne muscular dystrophy (DMD) in individuals who can walk starting at age six. Duvyzat is a suspension that is given orally in conjunction with corticosteroid therapy.

EMA Recommends EU Approval for Duvyzat (givinostat) to Treat Duchenne Muscular Dystrophy

#dmd #duchenne #ema #duvyzat #givinostat

👉 DMDWarrioR.com

1 0 0 0
Preview
Givinostat Appears to Stabilize Respiratory Function in DMD Patients who received givinostat showed a mean annual decline in forced vital capacity %-predicted of 3.6% before and 3.9% after ambulation loss.

#MDAConference: Boys with Duchenne muscular dystrophy treated with #givinostat and steroids had less decline in respiratory function after losing ambulation than those treated with steroids alone.

Read more: bit.ly/3FEOFTK

#RDAatMDA @mda.org

1 0 0 0
Preview
Long-Term Efficacy and Safety Data of DUVYZAT™ Presented at MDA Conference ITF Therapeutics LLC shares important long-term data on DUVYZAT™ (givinostat) for Duchenne muscular dystrophy, highlighting safety and effectiveness at MDA conference.

Long-Term Efficacy and Safety Data of DUVYZAT™ Presented at MDA Conference #USA #Dallas #DUVYZAT #Duchenne #givinostat

0 0 0 0

Like they paid our cost! So we would hit our max out of pocket. So the rest of the year insurance covers everything.

And we owe nothing.

This is the best present right now. I have no words. Just a lot of tears. The manufacturer of this drug is #ITF_therapeutics & the drug is #givinostat #duvyzat

2 0 1 0

While we live in Canada, I felt it was still important to share this post. When Emery was diagnosed with #Duchenne in 2012, we hoped for but didn’t have any certainty that new treatment would arise. Ems was part of the #Givinostat drug trial-his & others’ fearlessness will help change the 🌎 for #DMD

1 0 0 0
UK Approves Givinostat (Duvyzat) for Duchenne Muscular Dystrophy Treatment

UK Approves Givinostat (Duvyzat) for Duchenne Muscular Dystrophy Treatment

UK Approves Givinostat (Duvyzat) for Duchenne Muscular Dystrophy Treatment

Givinostat conditionally approved to treat patients with Duchenne muscular dystrophy (DMD)

#dmd #duchenne #bmd #becker #genetherapy #dmdwarrior #dmdwarriors #givinostat #duvyzat #mhra #uk #england

2 1 1 1
Early Access Programme for givinostat now open in UK

Early Access Programme for givinostat now open in UK

Early Access Programme for givinostat now open in UK

Early Access Programme for givinostat now open in UK

Early Access Programme for givinostat now open in UK

Early Access Programme for givinostat now open in UK

Early Access Programme for givinostat now open in UK

Early Access Programme for givinostat now open in UK

Early Access Programme for givinostat now open in UK 🎉💯

Givinostat is not yet approved in the UK, but the company is making it available free of charge in the UK until the regulators make a decision about approval. Read: dmdwarrior.com

Source: www.duchenneuk.org/givinostat-e...

#dmd #givinostat

0 0 0 0